» Articles » PMID: 26993606

Inactivation of RASA1 Promotes Melanoma Tumorigenesis Via R-Ras Activation

Abstract

Inactivation of Ras GTPase activating proteins (RasGAPs) can activate Ras, increasing the risk for tumor development. Utilizing a melanoma whole genome sequencing (WGS) data from 13 patients, we identified two novel, clustered somatic missense mutations (Y472H and L481F) in RASA1 (RAS p21 protein activator 1, also called p120RasGAP). We have shown that wild type RASA1, but not identified mutants, suppresses soft agar colony formation and tumor growth of BRAF mutated melanoma cell lines via its RasGAP activity toward R-Ras (related RAS viral (r-ras) oncogene homolog) isoform. Moreover, R-Ras increased and RASA1 suppressed Ral-A activation among Ras downstream effectors. In addition to mutations, loss of RASA1 expression was frequently observed in metastatic melanoma samples on melanoma tissue microarray (TMA) and a low level of RASA1 mRNA expression was associated with decreased overall survival in melanoma patients with BRAF mutations. Thus, these data support that RASA1 is inactivated by mutation or by suppressed expression in melanoma and that RASA1 plays a tumor suppressive role by inhibiting R-Ras, a previously less appreciated member of the Ras small GTPases.

Citing Articles

A Systematic Compilation of Human SH3 Domains: A Versatile Superfamily in Cellular Signaling.

Mehrabipour M, Kazemein Jasemi N, Dvorsky R, Ahmadian M Cells. 2023; 12(16).

PMID: 37626864 PMC: 10453029. DOI: 10.3390/cells12162054.


METTL3/YTHDF2 m6A axis promotes the malignant progression of bladder cancer by epigenetically suppressing RRAS.

Chen J, Chen D, Wang D, Xiao Y, Zhu S, Xu X Oncol Rep. 2023; 49(5).

PMID: 36960869 PMC: 10086563. DOI: 10.3892/or.2023.8531.


miR-188-5p promotes oxaliplatin resistance by targeting RASA1 in colon cancer cells.

Zhu X, Luo X, Song Z, Jiang S, Long X, Gao X Oncol Lett. 2021; 21(6):481.

PMID: 33968197 PMC: 8100964. DOI: 10.3892/ol.2021.12742.


Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.

Banyai L, Trexler M, Kerekes K, Csuka O, Patthy L Elife. 2021; 10.

PMID: 33427197 PMC: 7877913. DOI: 10.7554/eLife.59629.


Role of RASA1 in cancer: A review and update (Review).

Zhang Y, Li Y, Wang Q, Su B, Xu H, Sun Y Oncol Rep. 2020; 44(6):2386-2396.

PMID: 33125148 PMC: 7610306. DOI: 10.3892/or.2020.7807.


References
1.
Arafeh R, Qutob N, Emmanuel R, Keren-Paz A, Madore J, Elkahloun A . Recurrent inactivating RASA2 mutations in melanoma. Nat Genet. 2015; 47(12):1408-10. PMC: 4954601. DOI: 10.1038/ng.3427. View

2.
King P, Lubeck B, Lapinski P . Nonredundant functions for Ras GTPase-activating proteins in tissue homeostasis. Sci Signal. 2013; 6(264):re1. PMC: 5483993. DOI: 10.1126/scisignal.2003669. View

3.
Yue Y, Lypowy J, Hedhli N, Abdellatif M . Ras GTPase-activating protein binds to Akt and is required for its activation. J Biol Chem. 2004; 279(13):12883-9. DOI: 10.1074/jbc.M312308200. View

4.
Whittaker S, Theurillat J, Van Allen E, Wagle N, Hsiao J, Cowley G . A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 2013; 3(3):350-62. PMC: 3606893. DOI: 10.1158/2159-8290.CD-12-0470. View

5.
Papa A, Wan L, Bonora M, Salmena L, Song M, Hobbs R . Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function. Cell. 2014; 157(3):595-610. PMC: 4098792. DOI: 10.1016/j.cell.2014.03.027. View